GPR56/ADGRG1 is associated with response to antidepressant treatment
It is not fully understood why some patients respond or do not respond to antidepressant treatment. Here the authors show that in the blood of individuals with depression, GPR56 expression increases in responders to antidepressant treatment, but not in non-responders.
Enregistré dans:
Auteurs principaux: | Raoul Belzeaux, Victor Gorgievski, Laura M. Fiori, Juan Pablo Lopez, Julien Grenier, Rixing Lin, Corina Nagy, El Chérif Ibrahim, Eduardo Gascon, Philippe Courtet, Stéphane Richard-Devantoy, Marcelo Berlim, Eduardo Chachamovich, Jean-François Théroux, Sylvie Dumas, Bruno Giros, Susan Rotzinger, Claudio N. Soares, Jane A. Foster, Naguib Mechawar, Gregory G. Tall, Eleni T. Tzavara, Sidney H. Kennedy, Gustavo Turecki |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Nature Portfolio
2020
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/3469c4a94a4c4f539ae3e87d5f59f012 |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
The role of GPR56/ADGRG1 in health and disease
par: Abhishek Kumar Singh, et autres
Publié: (2021) -
Conserved residues in the extracellular loop 2 regulate Stachel-mediated activation of ADGRG2
par: Abanoub A. Gad, et autres
Publié: (2021) -
Whole-genome sequencing identifies ADGRG6 enhancer mutations and FRS2 duplications as angiogenesis-related drivers in bladder cancer
par: Song Wu, et autres
Publié: (2019) -
Orphan GPR61, GPR62 and GPR135 receptors and the melatonin MT2 receptor reciprocally modulate their signaling functions
par: Atsuro Oishi, et autres
Publié: (2017) -
The polymicrogyria-associated GPR56 promoter preferentially drives gene expression in developing GABAergic neurons in common marmosets
par: Ayako Y. Murayama, et autres
Publié: (2020)